CD274 and neoplasm: Other promising targets in combination with anti-PD-L1 are the anti-LAG-3 monoclonal antibody therapy, that in a Phase II study met the expansion criteria in SCLC and two other tumour types [53], and Delta-like ligand 3 (DLL3), with many different ongoing Phase I/II trials with BiTE antibodies and CAR-T therapies [54–56].